However, as more recent data are collected, they show that risk for recurrent and new cancer in patients with IBD is not increased by thiopurines or anti-TNFα agents [53], and possibly not even by new biologics such as VDZ and UST [59]. The gene discussed is TNF; the disease is inflammatory bowel disease.